Cargando…

Aldoxorubicin: a tumor-targeted doxorubicin conjugate for relapsed or refractory soft tissue sarcomas

Despite available therapies after initial systemic therapy, prognosis remains poor in relapsed or refractory soft tissue sarcomas (STS). The rational and clinical development of novel agents to improve outcomes in this area of high unmet need is desperately warranted. Aldoxorubicin is a prodrug of d...

Descripción completa

Detalles Bibliográficos
Autores principales:	Gong, Jun, Yan, Jessica, Forscher, Charles, Hendifar, Andrew
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Dove Medical Press 2018
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5896668/ https://www.ncbi.nlm.nih.gov/pubmed/29670334 http://dx.doi.org/10.2147/DDDT.S140638

Ejemplares similares

Spotlight on aldoxorubicin (INNO-206) and its potential in the treatment of soft tissue sarcomas: evidence to date
por: Cranmer, Lee D
Publicado: (2019)

Pharmacokinetic study of aldoxorubicin in patients with solid tumors
por: Mita, Monica M., et al.
Publicado: (2014)

Therapeutic Efficacy of Aldoxorubicin in an Intracranial Xenograft Mouse Model of Human Glioblastoma()()
por: Marrero, Luis, et al.
Publicado: (2014)

Aldoxorubicin and Temozolomide combination in a xenograft mice model of human glioblastoma
por: Da Ros, Martina, et al.
Publicado: (2018)

Results of a phase I dose escalation study of eltrombopag in patients with advanced soft tissue sarcoma receiving doxorubicin and ifosfamide
por: Chawla, Sant P, et al.
Publicado: (2013)

A phase II study of temsirolimus and liposomal doxorubicin for patients with recurrent and refractory bone and soft tissue sarcomas
por: Trucco, Matteo M., et al.
Publicado: (2018)

Targeted therapy for sarcomas
por: Forscher, Charles, et al.
Publicado: (2014)

Salinomycin increases chemosensitivity to the effects of doxorubicin in soft tissue sarcomas
por: Liffers, Sven-T, et al.
Publicado: (2013)

High cumulative doxorubicin dose for advanced soft tissue sarcoma
por: Tian, Zhichao, et al.
Publicado: (2020)

Epirubicin is not Superior to Doxorubicin in the Treatment of Advanced Soft Tissue Sarcomas.The Experience of the EORTC Soft Tissue and Bone Sarcoma Group
por: Nielsen, Ole S., et al.
Publicado: (2000)

Risk Factors for Occurrence and Relapse of Soft Tissue Sarcoma
por: Weskamp, Pia, et al.
Publicado: (2022)

Comparison between trabectedin and doxorubicin in soft-tissue sarcomas-reply letter
por: Dang, Jing-Yi, et al.
Publicado: (2022)

Irinotecan Plus Doxorubicin Hydrochloride Liposomes for Relapsed or Refractory Wilms Tumor
por: Wang, Juan, et al.
Publicado: (2021)

Long-term cure of soft tissue sarcoma with pegylated-liposomal doxorubicin after doxorubicin and ifosfamide failure
por: Savani, Malvi, et al.
Publicado: (2019)

Neoadjuvant and adjuvant doxorubicin chemotherapy in a case of feline soft tissue sarcoma
por: Torrigiani, Filippo, et al.
Publicado: (2019)

Targeted Treatment of Soft-Tissue Sarcoma
por: Riskjell, Anne Iren, et al.
Publicado: (2023)

REGOSARC: Regorafenib versus placebo in doxorubicin‐refractory soft‐tissue sarcoma—A quality‐adjusted time without symptoms of progression or toxicity analysis
por: Berry, Vincent, et al.
Publicado: (2017)

Cost-Effectiveness of Olaratumab in Combination with Doxorubicin for Patients with Soft Tissue Sarcoma in the United States
por: Zuluaga-Sanchez, Santiago, et al.
Publicado: (2018)

Real-world experience with doxorubicin and olaratumab in soft tissue sarcomas in England and Northern Ireland
por: Gennatas, Spyridon, et al.
Publicado: (2020)

Eribulin as a first-line treatment for soft tissue sarcoma patients with contraindications for doxorubicin
por: Tsuchihashi, Kenji, et al.
Publicado: (2020)

Soft Tissue Sarcoma Study: Association of Genetic Alterations in the Apoptosis Pathways with Chemoresistance to Doxorubicin
por: Kirilin, Evgeny M., et al.
Publicado: (2022)

High-dose epirubicin is not an alternative to standard-dose doxorubicin in the treatment of advanced soft tissue sarcomas. A study of the EORTC soft tissue and bone sarcoma group.
por: Nielsen, O. S., et al.
Publicado: (1998)

Weekly Gemcitabine and Docetaxel in Refractory Soft Tissue Sarcoma: A Retrospective Analysis
por: Lee, Ha-young, et al.
Publicado: (2012)

Therapeutic Targets for Bone and Soft-Tissue Sarcomas
por: Miwa, Shinji, et al.
Publicado: (2019)

Targeted therapies for the treatment of soft tissue sarcoma
por: Fuchs, Jeffrey W., et al.
Publicado: (2023)

Phase 1 study of olaratumab plus doxorubicin in Japanese patients with advanced soft‐tissue sarcoma
por: Yonemori, Kan, et al.
Publicado: (2018)

Comparison between trabectedin and doxorubicin in soft-tissue sarcomas: a systematic review and meta-analysis
por: Dang, Jingyi, et al.
Publicado: (2021)

Similar additive effects of doxorubicin in combination with photon or proton irradiation in soft tissue sarcoma models
por: Bernardo, Teresa, et al.
Publicado: (2023)

Inhibition of AKT-Signaling Sensitizes Soft Tissue Sarcomas (STS) and Gastrointestinal Stromal Tumors (GIST) to Doxorubicin via Targeting of Homology-Mediated DNA Repair
por: Boichuk, Sergei, et al.
Publicado: (2020)

Soft-tissue Sarcomas
por: Vodanovich, Domagoj Ante, et al.
Publicado: (2018)

Targeting glutamine metabolism slows soft tissue sarcoma growth
por: Lee, Pearl, et al.
Publicado: (2020)

Combination therapy with Olaratumab/doxorubicin in advanced or metastatic soft tissue sarcoma -a single-Centre experience
por: Striefler, Jana Käthe, et al.
Publicado: (2020)

Efficacy and Safety of Anlotinib Combined with Liposomal Doxorubicin Followed by Anlotinib Maintenance in Metastatic Soft Tissue Sarcomas
por: Liu, Zhiyong, et al.
Publicado: (2021)

Quality of life of patients with soft tissue sarcoma treated with doxorubicin in the ANNOUNCE phase III clinical trial
por: Van Tine, Brian A, et al.
Publicado: (2022)

Tumor-targeting Salmonella typhimurium A1-R in combination with doxorubicin eradicate soft tissue sarcoma in a patient-derived orthotopic xenograft (PDOX) model
por: Murakami, Takashi, et al.
Publicado: (2016)

Significance of Circulating Tumor Cells in Soft Tissue Sarcoma
por: Nicolazzo, Chiara, et al.
Publicado: (2015)

The PTEN Tumor Suppressor Gene in Soft Tissue Sarcoma
por: Stefano, Sioletic, et al.
Publicado: (2019)

Gemcitabine, Navelbine, and Doxorubicin as Treatment for Patients with Refractory or Relapsed T-Cell Lymphoma
por: Qian, Zhengzi, et al.
Publicado: (2015)

Elevated HERV-K Expression in Soft Tissue Sarcoma Is Associated with Worsened Relapse-Free Survival
por: Giebler, Maria, et al.
Publicado: (2018)

Retroperitoneal soft tissue sarcoma
por: Zepeda, Ernesto, et al.
Publicado: (2007)

Cannot write session to /tmp/vufind_sessions/sess_rd5at3pnjv23f58q29rkab1lka